Nishant Agrawal

Surgeon, scientist, father, dreamer, team-player, and compassionate idealist

[Johns Hopkins OHNS @hopkins_ent]

#TBT to when @HNCancerDoc Nishant Agrawal was a resident at Johns Hopkins! We recently reconnected with him and learned how his time at Johns Hopkins shaped his career. https://t.co/2DoGnJKCoi @UChicagoOHNS

[UChicagoCancerCenter @UCCancerCenter]

Experts at @UChicagoMed successfully treated and cured stage IV oral cancer patient Pat Sirvinskas with a unique approach that spared her tongue. Hear her story in her own words. @HNCancerDoc @AriRosenbergMD @ajuloorimd @UChicagoOHNS https://t.co/ANC0OqufTz

[UChicagoCancerCenter @UCCancerCenter]

We are proud to announce that @UCCancerCenter has been ranked #1 in Illinois and #12 in the nation in the latest U.S. News & World Report's Best Hospitals. We are committed to providing highest quality care to cancer patients.
https://t.co/tNYF2yjrjj

[UChicago Medicine @UChicagoMed]

U.S. News & World Report's Best Hospitals list ranked University of Chicago Medical Center's Cancer and ENT programs highest in Illinois. Additionally, UCMC is one of only 25 hospitals nationwide to have at least 10 ranked specialties. https://t.co/CL6ITFUDcE

[UChicagoOHNS @UChicagoOHNS]

A truly special night celebrating the graduation of our chief residents Drs. Warren and Patel! They were a special duo who will be sorely missed 🥹 They are both off for fellowship @EmoryENT and we look forward to their future accomplishments #ENT #Residency #IamOto

[Ari Rosenberg @AriRosenbergMD]

Excited that our OPTIMA II trial is out in @JAMAOnc! Neoadjuvant nivo/chemo -> response-adaptive treatment for HPV+ oropharyngeal cancer @eevokes @lab_pearson @ajuloorimd @HNCancerDoc @EAB_ENT @SysmexInostics @UCCancerCenter @UChicagoMed @UChicagoHemOnc
https://t.co/l6hQvg2XnJ

[Pearson Lab @lab_pearson]

@AriRosenbergMD #OPTIMA2 HNSCC DE-ESCALATION study out today @JAMAOnc:

🧑‍🤝‍🧑Broad inclusion N2 to N3 and/or T3 to T4 HPV+
🙌Excellent OS
💪Chemo/IO induction has high pathCR rates
👄Super-low g-tube rates for max de-escalated pts (green KM curve line)

see: https://t.co/997C3W5KOR

[UChicagoCancerCenter @UCCancerCenter]

@AriRosenbergMD presents results from HB-200, an arenavirus-based vector therapy specifically targeted for HPV+ oropharyngeal cancers.
Neoadjuvant HB-200 could be a potential new therapy as induces T-cell responses and reduces ctHPV-DNA. #ASCO24
@UCCancerCenter @UChicagoMed

[Pearson Lab @lab_pearson]

@AriRosenbergMD at #asco24 sharing a first look at TARGET-HPV. Exciting HPV targeted chemo-immunotherapy neoadjuvant treatment with adaptive de-escalation. A great multi-D effort from @UCCancerCenter @UChicagoHemOnc @UChicagoOHNS @UChicagoRadonc

[UChicagoCancerCenter @UCCancerCenter]

Manu Sundaresan, 4th year undergrad student @UChicago presents an excellent poster at #AACR24 showing the association of higher levels of PDCD10 expression with poor prognosis in oral squamous cell carcinoma. @UCCancerCenter @HNCancerDoc @EIzumchenko

[UChicagoCancerCenter @UCCancerCenter]

Congratulations to Alka Singh on receiving “AACR Scholar in Training Award” for presenting important work on “Comprehensive characterization of mitochondrial mutational landscape in the evolution of adenocarcinoma.”
@HNCancerDoc @EIzumchenko
@UCCancerCenter @UChicagoOHNS

[UChicagoOHNS @UChicagoOHNS]

So excited that Drs. Roxbury, Baroody, Shogan, Portugal, Pinto, @EAB_ENT @HNCancerDoc @GluthMichael @DrDanaSuskind have made the list! Such an incredible honor that reflects their dedication to patient care! 👏🏻🤩🤗 #TopDocs2024 #Chicago #ENT #IamOto @uchicagosurgery

[Ted Imbery @TedImbEARy]

An all star squad! #ChicagoTopDocs

[Ari Rosenberg @AriRosenbergMD]

ctDNA is a powerful dynamic biomarker with IO-based treatment; Need for prospective ctDNA adaptive immunotherapy trial designs such as our "SINERGY" trial in recurrent/metastatic #headandneckcancer (NCT05420948) @EIzumchenko @ajuloorimd @HNCancerDoc https://t.co/JDZ0lipvh0

[Head and Neck Cancer Alliance @hncalliance]

Has your head and neck tumor grown back? We are looking for people with a diagnosis of head and neck cancer caused by human papillomavirus 16 (HPV16) to enroll in a clinical research study. Clink the link to learn more: https://t.co/lPsrzjemq9

[Head and Neck Cancer Alliance @hncalliance]

Attention head and neck cancer fighters, survivors, and caregivers! Register now for the 2023 Head and Neck Cancer Symposium. This event is FREE and it is our first year with the option to attend in person (Indianapolis) or virtually.

Details: https://t.co/UacY2u6Kie

[UChicagoOHNS @UChicagoOHNS]

Please join us on Saturday September 2nd for our virtual #ENT program showcase! RSVP with the link below - Excited to meet future applicants! #TheMatch #OtoMatch #IamOto #Residency https://t.co/LK8rWDj5Uz

[Dr. Dana Suskind @DrDanaSuskind]

AI devices are almost certain to become electronic babysitters—just as previous generations of parents (understandably!) adopted TV as a tool for lightening caregiving duties.

Thank you to @WSJ for letting me weigh in on the peril—and promise—of this.
https://t.co/GP8kSymh5P

[UChicagoOHNS @UChicagoOHNS]

Proud to announce we have been ranked 32 nationally among #ENT programs in the @usnews annual report! This is a collective effort reflecting tremendous work and relentless dedication amongst the entire section @UChicagoMed @uchicagosurgery
https://t.co/5YnJHV62IX

[Head and Neck Cancer Alliance @hncalliance]

Don't miss (August 21st) our next free webinar - "Caregivers - How to care for yourself and your loved one with head and neck cancer."

Registration and all the details can be found here: https://t.co/0IMD17dXbl

#cancereducation #hnca #headandneckcancer #caregivers